New Treatment Perspectives in Eating Disorders: the Efficacy of Non-invasive Brain-directed Treatment
Primary Purpose
Eating Disorders, Binge Eating Disorder, Anorexia Nervosa
Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
AN Active tDCS
AN Sham tDCS
BED Active tDCS
BED Sham tDCS
Sponsored by
About this trial
This is an interventional treatment trial for Eating Disorders
Eligibility Criteria
Inclusion Criteria:
- Under-weight (BMI less than 5th percentile)1 with Clinical diagnosis of AN as described in the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
- Over-weight/Obesity (OW/OB) (BMI above the 85th percentile)1 with diagnosis of BED, or with food craving behaviors
- Ability to give informed consent under parents' surveillance and guidance
Exclusion Criteria:
- Having a comorbidity with an important medical condition;
- Having neurological diseases
- Having Epilepsy o family history of epilepsy
- Pregnant or planning to become pregnant;
- Suicide risk;
- Receiving counseling or psychological therapies during the study;
- Receiving a treatment for an eating disorder in the previous three months before the baseline screening visit.
Sites / Locations
- Bambino Gesù Hospital and Research InstituteRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Sham Comparator
Experimental
Sham Comparator
Arm Label
AN Active tDCS
AN Sham tDCS
BED Active tDCS
BED Sham tDCS
Arm Description
Treatment "as usual" plus experimental treatment
Treatment "as usual" plus placebo treatment
Treatment "as usual" plus experimental treatment
Treatment "as usual" plus placebo treatment
Outcomes
Primary Outcome Measures
The primary end-point of the study is the mean change in the Overcontrol composite score of Eating Disorder Inventory - Three (EDI-3) questionnaire, using an approach based on the magnitudes of change.
the mean change in the Overcontrol composite score of the EDI-3 questionnaire gives a measure of the basic characteristics of the eating disorders and is a prognostic measure of outcome of eating disorders. Indeed, patterns of treatment response revealed significantly changes in terms of reduced eating disorder symptoms and fewer psychological problems.
Secondary Outcome Measures
The proportion of patients in the two arms with improvement in the total scores of other psychopathological measures as the Yale-Brown-Cornell Eating Disorder Scale (YBC-EDS) questionnaire
The proportion of patients in the two arms with improvement in the total scores of other psychopathological measures as the BINGE EATING SCALE (BES) questionnaire
The proportion of patients in the two arms with improvement in the neuropsychological measure of executive control and reward sensitivity by the 'Bechara Iowa Gambling' Task
The proportion of patients in the two arms with improvement in the neuropsychological measure of the ability to stop by THE STOP-SIGNAL REACTION-TIME (SSRT) task.
The proportion of patients in the two arms with improvement in the neuropsychological measure of visual attention and task switching by the TRAIL MAKING TEST
The proportion of patients in the two arms with normalization of different physiological measures specifically the BMI index
The proportion of patients in the two arms with normalization of different physiological measures specifically the values of bloody pressure
The proportion of patients in the two arms with normalization of different physiological measures specifically the values of cardiac frequency
The proportion of patients in the two arms with normalization of different physiological measures specifically the values of body composition
In the AN group, significant changes in intra-cortical inhibitory/excitatory motor circuits using paired pulse TMS, measured as SICI/ICF: the ratio between MEPs amplitude (mV) conditioning stimulus and MEPs amplitude test stimulus alone for each ISI.
In the AN group, significant changes in sensory-motor integration using paired pulse TMS, measured as SICI/ICF: the ratio between MEPs amplitude (mV) conditioning stimulus (electrical stimulation) and MEP amplitude test stimulus alone for each ISI.
In the AN group, significant changes in cortical oscillatory patterns (synchronization and desynchronization) in theta, alpha and beta frequencies (Hz) over motor and premotor cortex, using TMS-EEG co-registration.
In the AN group, normalization of endogenous stress response, measured with CAR.
In the AN group, significant changes in cortical connectivity, through the analysis of the waveform, latency and cortical distribution of TMS-evoked potentials (TEPs) in micronV, using TMS-EEG co-registration.
In the AN group, significant changes in cortical reactivity in terms of TMS-evoked potentials (TEPs) amplitude for time domain (micronV) and frequency bands for spatial domain (Hz), using TMS-EEG co-registration.
In the AN group, significant changes in Cortical Plasticity evoked by repetitive TMS in terms of different MEP amplitude (mV) recorded at different time-points after repetitive TMS perturbations.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02382497
Brief Title
New Treatment Perspectives in Eating Disorders: the Efficacy of Non-invasive Brain-directed Treatment
Official Title
New Treatment Perspectives in Eating Disorders: the Efficacy of Non-invasive Brain-directed Treatment
Study Type
Interventional
2. Study Status
Record Verification Date
November 2021
Overall Recruitment Status
Recruiting
Study Start Date
July 2014 (undefined)
Primary Completion Date
July 2023 (Anticipated)
Study Completion Date
July 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Mariella Enoc
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The present study grounds on the possible role of hemispheric lateralization in Eating disorders (ED): specifically, hyperactivity of the right frontal regions in Anorexia Nervosa (AN), and hypoactivity of the right frontal regions in Binge Eating Disorder (BED) and food craving behaviors.
Therefore, the investigators hypothesized that active excitatory tDCS over left prefrontal cortex (PFC) (Anode left/cathode right) may aid in altering/resetting inter-hemispheric balance in AN patients, re-establish control over eating behaviors. On the contrary, active excitatory tDCS over right PFC (Anode right/cathode left) may aid in altering/resetting inter-hemispheric balance in BED patients and people with frequent food cravings, decreasing cravings/appetite binge eating behaviors.
Detailed Description
The study design is randomized stratified, double blind, add-on, placebo-controlled.
A group of children and adolescents with AN will be selected and randomly assigned to two different conditions: treatment "as usual" plus experimental treatment (active tDCS); treatment "as usual" plus placebo treatment (sham tDCS).
Similarly, a group of children and adolescents with Over-weight/Obesity (OW/OB) and BED will be selected and assigned with randomized stratified sampling to the following conditions: treatment "as usual" plus experimental treatment (active tDCS); treatment "as usual" plus placebo treatment (sham tDCS).
In this project, the investigators will work to understand whether a brain-based treatment, with the use of tDCS, can improve the outcome of patients with eating disorders.
The investigators will test whether tDCS treatment produces improvements in under-eating and over-eating diseases, such us AN and OW/OB with BED and food craving.
Our overarching goal is to provide a scientific foundation for devising new rehabilitation strategies in ED.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Eating Disorders, Binge Eating Disorder, Anorexia Nervosa
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
160 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
AN Active tDCS
Arm Type
Experimental
Arm Description
Treatment "as usual" plus experimental treatment
Arm Title
AN Sham tDCS
Arm Type
Sham Comparator
Arm Description
Treatment "as usual" plus placebo treatment
Arm Title
BED Active tDCS
Arm Type
Experimental
Arm Description
Treatment "as usual" plus experimental treatment
Arm Title
BED Sham tDCS
Arm Type
Sham Comparator
Arm Description
Treatment "as usual" plus placebo treatment
Intervention Type
Device
Intervention Name(s)
AN Active tDCS
Other Intervention Name(s)
Brain Stim
Intervention Description
The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.
tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.
The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement.
Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.
Intervention Type
Device
Intervention Name(s)
AN Sham tDCS
Other Intervention Name(s)
Brain Stim Sham
Intervention Description
The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
Intervention Type
Device
Intervention Name(s)
BED Active tDCS
Other Intervention Name(s)
Brain Stim
Intervention Description
The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.
tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.
For the OW/OB with diagnosis of BE, or food craving, the anode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement.
Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.
Intervention Type
Device
Intervention Name(s)
BED Sham tDCS
Other Intervention Name(s)
Brain Stim
Intervention Description
The same electrode placement will be used as in the stimulation conditions (right anodal/left cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
Primary Outcome Measure Information:
Title
The primary end-point of the study is the mean change in the Overcontrol composite score of Eating Disorder Inventory - Three (EDI-3) questionnaire, using an approach based on the magnitudes of change.
Description
the mean change in the Overcontrol composite score of the EDI-3 questionnaire gives a measure of the basic characteristics of the eating disorders and is a prognostic measure of outcome of eating disorders. Indeed, patterns of treatment response revealed significantly changes in terms of reduced eating disorder symptoms and fewer psychological problems.
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
The proportion of patients in the two arms with improvement in the total scores of other psychopathological measures as the Yale-Brown-Cornell Eating Disorder Scale (YBC-EDS) questionnaire
Time Frame
6 weeks
Title
The proportion of patients in the two arms with improvement in the total scores of other psychopathological measures as the BINGE EATING SCALE (BES) questionnaire
Time Frame
6 weeks
Title
The proportion of patients in the two arms with improvement in the neuropsychological measure of executive control and reward sensitivity by the 'Bechara Iowa Gambling' Task
Time Frame
6 weeks
Title
The proportion of patients in the two arms with improvement in the neuropsychological measure of the ability to stop by THE STOP-SIGNAL REACTION-TIME (SSRT) task.
Time Frame
6 weeks
Title
The proportion of patients in the two arms with improvement in the neuropsychological measure of visual attention and task switching by the TRAIL MAKING TEST
Time Frame
6 weeks
Title
The proportion of patients in the two arms with normalization of different physiological measures specifically the BMI index
Time Frame
12 months follow up
Title
The proportion of patients in the two arms with normalization of different physiological measures specifically the values of bloody pressure
Time Frame
12 months follow up
Title
The proportion of patients in the two arms with normalization of different physiological measures specifically the values of cardiac frequency
Time Frame
12 months follow up
Title
The proportion of patients in the two arms with normalization of different physiological measures specifically the values of body composition
Time Frame
12 months follow up
Title
In the AN group, significant changes in intra-cortical inhibitory/excitatory motor circuits using paired pulse TMS, measured as SICI/ICF: the ratio between MEPs amplitude (mV) conditioning stimulus and MEPs amplitude test stimulus alone for each ISI.
Time Frame
6 weeks
Title
In the AN group, significant changes in sensory-motor integration using paired pulse TMS, measured as SICI/ICF: the ratio between MEPs amplitude (mV) conditioning stimulus (electrical stimulation) and MEP amplitude test stimulus alone for each ISI.
Time Frame
6 weeks
Title
In the AN group, significant changes in cortical oscillatory patterns (synchronization and desynchronization) in theta, alpha and beta frequencies (Hz) over motor and premotor cortex, using TMS-EEG co-registration.
Time Frame
6 weeks
Title
In the AN group, normalization of endogenous stress response, measured with CAR.
Time Frame
6 months follow up
Title
In the AN group, significant changes in cortical connectivity, through the analysis of the waveform, latency and cortical distribution of TMS-evoked potentials (TEPs) in micronV, using TMS-EEG co-registration.
Time Frame
6 weeks
Title
In the AN group, significant changes in cortical reactivity in terms of TMS-evoked potentials (TEPs) amplitude for time domain (micronV) and frequency bands for spatial domain (Hz), using TMS-EEG co-registration.
Time Frame
6 weeks
Title
In the AN group, significant changes in Cortical Plasticity evoked by repetitive TMS in terms of different MEP amplitude (mV) recorded at different time-points after repetitive TMS perturbations.
Time Frame
6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Under-weight (BMI less than 5th percentile)1 with Clinical diagnosis of AN as described in the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
Over-weight/Obesity (OW/OB) (BMI above the 85th percentile)1 with diagnosis of BED, or with food craving behaviors
Ability to give informed consent under parents' surveillance and guidance
Exclusion Criteria:
Having a comorbidity with an important medical condition;
Having neurological diseases
Having Epilepsy o family history of epilepsy
Pregnant or planning to become pregnant;
Suicide risk;
Receiving counseling or psychological therapies during the study;
Receiving a treatment for an eating disorder in the previous three months before the baseline screening visit.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Floriana Costanzo
Phone
0668597091
Email
floriana.costanzo@opbg.net
First Name & Middle Initial & Last Name or Official Title & Degree
Valeria Zanna
Email
valeira.zanna@opbg.net
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stefano Vicari
Organizational Affiliation
Bambino Gesù Hospital and Research Institute
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Floriana Costanzo
Organizational Affiliation
Bambino Gesù Hospital and Research Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Bambino Gesù Hospital and Research Institute
City
Rome
ZIP/Postal Code
00165
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chiara Mennini
Phone
06-68592572
Email
chiara.mennini@opbg.net
First Name & Middle Initial & Last Name & Degree
Rita Alparone
Phone
06-68593580
Email
rita.alparone@opbg.net
12. IPD Sharing Statement
Citations:
PubMed Identifier
21320389
Citation
Brunoni AR, Amadera J, Berbel B, Volz MS, Rizzerio BG, Fregni F. A systematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation. Int J Neuropsychopharmacol. 2011 Sep;14(8):1133-45. doi: 10.1017/S1461145710001690. Epub 2011 Feb 15.
Results Reference
background
PubMed Identifier
30083095
Citation
Costanzo F, Menghini D, Maritato A, Castiglioni MC, Mereu A, Varuzza C, Zanna V, Vicari S. New Treatment Perspectives in Adolescents With Anorexia Nervosa: The Efficacy of Non-invasive Brain-Directed Treatment. Front Behav Neurosci. 2018 Jul 20;12:133. doi: 10.3389/fnbeh.2018.00133. eCollection 2018.
Results Reference
result
Learn more about this trial
New Treatment Perspectives in Eating Disorders: the Efficacy of Non-invasive Brain-directed Treatment
We'll reach out to this number within 24 hrs